During the last session, Corcept Therapeutics Incorporated (NASDAQ:CORT)’s traded shares were 0.4 million, with the beta value of the company hitting 0.68. At the end of the trading day, the stock’s price was $21.53, reflecting an intraday loss of -0.87% or -$0.19. The 52-week high for the CORT share is $31.18, that puts it down -44.82 from that peak though still a striking 23.73% gain since the share price plummeted to a 52-week low of $16.42. The company’s market capitalization is $2.45B, and the average intraday trading volume over the past 10 days was 0.44 million shares, and the average trade volume was 526.48K shares over the past three months.
Corcept Therapeutics Incorporated (CORT) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.50. CORT has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.16.
Corcept Therapeutics Incorporated (NASDAQ:CORT) trade information
Corcept Therapeutics Incorporated (CORT) registered a -0.87% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.87% in intraday trading to $21.53 this Friday, 09/03/21, hitting a weekly high. The stock’s 5-day price performance is 0.00%, and it has moved by -0.51% in 30 days. Based on these gigs, the overall price performance for the year is 12.84%. The short interest in Corcept Therapeutics Incorporated (NASDAQ:CORT) is 7.64 million shares and it means that shorts have 12.1 day(s) to cover.
The consensus price target of analysts on Wall Street is $25.25, which implies an increase of 14.73% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $16.00 and $35.00 respectively. As a result, CORT is trading at a discount of -62.56% off the target high and 25.69% off the low.
Corcept Therapeutics Incorporated (CORT) estimates and forecasts
Statistics show that Corcept Therapeutics Incorporated has underperformed its competitors in share price, compared to the industry in which it operates. Corcept Therapeutics Incorporated (CORT) shares have gone down -9.35% during the last six months, with a year-to-date growth rate less than the industry average at -3.53% against 18.50. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to shrink -30.40% this quarter and then jump 17.60% in the quarter after that. In the rating firms’ projections, revenue will increase 5.30% compared to the previous financial year.
Revenue for the current quarter is expected to be $91.59 million as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to $97.65 million by the end of Sep 2021.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 74.60%. While earnings are projected to return 11.10% in 2021.
Corcept Therapeutics Incorporated is due to release its next quarterly earnings between November 01 and November 05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Corcept Therapeutics Incorporated (NASDAQ:CORT)’s Major holders
Corcept Therapeutics Incorporated insiders own 9.91% of total outstanding shares while institutional holders control 72.00%, with the float percentage being 79.93%. Blackrock Inc. is the largest shareholder of the company, while 291 institutions own stock in it. As of Mar 30, 2021, the company held over 16.17 million shares (or 13.95% of all shares), a total value of $384.71 million in shares.
The next largest institutional holding, with 12.39 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 10.69% of outstanding shares. At the market price on Mar 30, 2021, these shares were valued at $294.7 million.
Also, the Mutual Funds coming in first place with the largest holdings of Corcept Therapeutics Incorporated (CORT) shares are iShares Core S&P Smallcap ETF and Federated Hermes Kaufmann Fund. Data provided on Jun 29, 2021 indicates that iShares Core S&P Smallcap ETF owns about 7.08 million shares. This amounts to just over 6.11 percent of the company’s overall shares, with a $155.76 million market value. The same data shows that the other fund manager holds slightly less at 4.94 million, or about 4.26% of the stock, which is worth about $112.56 million.